Cargando…

Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study

BACKGROUND: Daclizumab is a humanized monoclonal antibody against CD25 that modulates interleukin 2 signaling. The SELECT TRILOGY of clinical studies (SELECT/SELECTION/SELECTED) evaluated the safety and efficacy of daclizumab in patients with relapsing-remitting multiple sclerosis (RRMS). We report...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gold, Ralf, Radue, Ernst-Wilhelm, Giovannoni, Gavin, Selmaj, Krzysztof, Havrdova, Eva, Stefoski, Dusan, Sprenger, Till, Montalban, Xavier, Cohan, Stanley, Umans, Kimberly, Greenberg, Steven J., Ozen, Gulden, Elkins, Jacob
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962457/ https://www.ncbi.nlm.nih.gov/pubmed/27461166 http://dx.doi.org/10.1186/s12883-016-0635-y

Ejemplares similares

Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study
por: Gold, Ralf, et al.
Publicado: (2020)

Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis
por: Giovannoni, Gavin, et al.
Publicado: (2013)

CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS
por: Elkins, J., et al.
Publicado: (2015)

Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program
por: Gold, Ralf, et al.
Publicado: (2016)

Improved cognitive outcomes in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study
por: Benedict, Ralph HB, et al.
Publicado: (2017)

Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE
por: Cohan, Stanley, et al.
Publicado: (2017)

Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis
por: Tran, Jonathan Q, et al.
Publicado: (2016)

Review of daclizumab and its therapeutic potential in the treatment of relapsing–remitting multiple sclerosis
por: Reardon, Jennifer, et al.
Publicado: (2013)

Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis
por: Cohan, Stanley
Publicado: (2016)

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
por: Kuhle, Jens, et al.
Publicado: (2015)

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
por: Giovannoni, Gavin, et al.
Publicado: (2016)

Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis
por: Krueger, James G., et al.
Publicado: (2016)

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2015)

Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review
por: Giovannoni, Gavin, et al.
Publicado: (2022)

Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial
por: Olsson, Tomas, et al.
Publicado: (2014)

Effect of delayed‐release dimethyl fumarate on no evidence of disease activity in relapsing–remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies
por: Havrdova, E., et al.
Publicado: (2017)

Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing–remitting multiple sclerosis (RRMS)
por: Gold, Ralf, et al.
Publicado: (2015)

Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study
por: Giovannoni, Gavin, et al.
Publicado: (2023)

Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis
por: Cohan, Stanley L., et al.
Publicado: (2019)

No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing–Remitting Multiple Sclerosis
por: Nixon, Richard, et al.
Publicado: (2014)

Pharmacodynamic effects of daclizumab in the intrathecal compartment
por: Komori, Mika, et al.
Publicado: (2017)

Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination
por: Kappos, Ludwig, et al.
Publicado: (2021)

Endocarditis following ocrelizumab in relapsing-remitting MS
por: Faissner, Simon, et al.
Publicado: (2020)

Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing–Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies
por: Gold, Ralf, et al.
Publicado: (2016)

Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials
por: Viglietta, Vissia, et al.
Publicado: (2015)

Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study
por: Coles, Alasdair J., et al.
Publicado: (2023)

White matter lesion location correlates with disability in relapsing multiple sclerosis
por: Gaetano, Laura, et al.
Publicado: (2020)

Spotlight on daclizumab: its potential in the treatment of multiple sclerosis
por: Milo, Ron, et al.
Publicado: (2016)

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
por: Kappos, Ludwig, et al.
Publicado: (2015)

Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA
por: Radue, Ernst-Wilhelm, et al.
Publicado: (2017)

Thalamic–hippocampal–prefrontal disruption in relapsing–remitting multiple sclerosis
por: Kern, Kyle C., et al.
Publicado: (2014)

Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis
por: Lin, Yen Chih, et al.
Publicado: (2015)

Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing–remitting multiple sclerosis: the CLARITY Extension study
por: Comi, Giancarlo, et al.
Publicado: (2018)

The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing–remitting multiple sclerosis
por: Derfuss, T, et al.
Publicado: (2020)

Natalizumab improves ambulation in relapsing−remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM
por: Voloshyna, N, et al.
Publicado: (2015)

Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison
por: Cohan, Stanley, et al.
Publicado: (2021)

Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial
por: Hemmer, Bernhard, et al.
Publicado: (2023)

Relapsing/remitting type 1 diabetes
por: van Megen, Kayleigh M., et al.
Publicado: (2017)

Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2015)

Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy in MS
por: Scheibe, Franziska, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_413god39lf5tbctpui2190v7qa